Cancer Research Sa
Adelaide, South Australia 5011
10 studies enrolling now · 18 studies all time
What they study most
Adenoid Cystic Carcinoma, Advanced Breast Cancer, Advanced Non-Small Cell Lung Cancer, Advanced Non-Small Cell Non-Squamous Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Advanced Solid Tumor, Advanced Solid Tumors, Biliary Tract Neoplasms, Breast Cancer, Carcinoma, Non-Small-Cell Lung, Cervical Cancer, Colorectal Neoplasms
Studies at this site
- A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer — Recruiting now
- A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies — Recruiting now
- A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) — Recruiting now
- A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors — Recruiting now
- Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer — Recruiting now
- Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer — Recruiting now
- Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) — Recruiting now
- A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence — Recruiting now
- Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors — Recruiting now
- ARC101 in Advanced Solid Tumors — Recruiting now
- A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer — Running, not enrolling
- A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer — Running, not enrolling
- Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) — Running, not enrolling
- THIO Sequenced With Cemiplimab in Advanced NSCLC — Running, not enrolling
- Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer — Running, not enrolling
- Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer — Stopped early
- Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer — Stopped early
- Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC — Running, not enrolling